Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients.

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Abstract Text:

Kazuki Tanimoto,Akihiro Kaneko,Shigenobu Suzuki,Naohiro Sekiguchi,Takashi Watanabe,Yukio Kobayashi,Yoshikazu Kagami,Akiko Miyagi Maeshima,Yoshihiro Matsuno,Kensei Tobinai,

BACKGROUND: Although primary ocular adnexal MALT (mucosa-associated lymphoid tissue) lymphoma (POAML) is a recently recognized unique entity, its natural history, prognostic factors, behavior of progression and death, and standard initial management have not been fully elucidated. METHODS: The data of 114 patients with histologically verified POAML who were treated at our institution between 1970 and 2003 were retrospectively analyzed. RESULTS: With a median follow-up duration of 5.7 years (0.6-34.0), estimated overall survival (OS) rate and progression-free survival (PFS) rate at 10 years was 89% and 57%, respectively. Thirteen (11%) patients died, but only three (3%) of them due to progressive lymphoma. Thirty-one (27%) patients progressed: eight who progressed at contra lateral sites were limited to those who had initially involved in the orbit (P = 0.036) and their OS and PFS were significantly longer (P = 0.035 and 0.039, respectively). Patients who initially received radiation-containing therapy were superior in PFS but not in OS to those initially treated with other modalities (P = 0.016 and 0.091, respectively). When we compared the outcomes of the observation cohort and the immediate therapy cohort, there were no significant differences in OS and PFS (P = 0.499 and 0.073, respectively). CONCLUSIONS: The majority of patients with POAML showed the behaviors of localized and indolent diseases. Our preliminary observation that no initial therapy is an acceptable approach for selected patients was confirmed. Considering the possible heterogeneity of POAML among initial sites, further investigations are warranted.

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Publishing Authors By Initials

K Tanimoto,A Kaneko,S Suzuki,N Sekiguchi,T Watanabe,Y Kobayashi,Y Kagami,AM Maeshima,Y Matsuno,K Tobinai,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Japanese journal of clinical oncology

VOLUME: 37

Page Numbers: 337-44

Journal Abbreviation: Jpn. J. Clin. Oncol.

ISSN: 1465-3621

DAY: 11

MONTH: 06

YEAR: 2007

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 313225

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients.

AFFILIATION: Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital and Research Institute, Tokyo, Japan.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Jpn J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients Related Publications

• Nocardia exalbida brain abscess in a patient with follicular lymphoma.
• Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208.
• Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study.
• Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients.
• Proteasome inhibitor, bortezomib, for myeloma and lymphoma.